Evidence map›Paper›PMID 38900215›Full record

SynthesisInternational journal of clinical oncology2024

Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022.

Kazuki Nozawa, Yukinori Ozaki, Tetsuhiro Yoshinami, Takamichi Yokoe, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miura, Makoto Endo, Shingo Yano and 17 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Mapping supportive-care evidence for febrile neutropenia prevention in breast cancer chemotherapy: a bibliometric analysis of long-acting G-CSF prophylaxis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  2. Article
  3. Article
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Kazuki NozawaDepartment of Advanced Clinical Research and Development, Nagoya City University, Graduate School of Medical Sciences, Aichi, Japan. kazuki.nozawa7@gmail.com.ORCID http://orcid.org/0000-0002-0277-8196
Yukinori OzakiDepartment of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Tetsuhiro YoshinamiDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Takamichi YokoeDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Hiroshi NishioDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Kenji TsuchihashiDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University, Fukuoka, Japan.
Eiki IchiharaCenter for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
Yuji MiuraDepartment of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Makoto EndoDepartment of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
Shingo YanoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Dai MaruyamaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Nobuyuki SusumuDepartment of Obstetrics and Gynecology, International University of Health and Welfare Narita Hospital, Chiba, Japan.
Munetaka TakekumaDepartment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Takashi MotohashiDepartment of Obstetrics and Gynecology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
Mamoru ItoDepartment of Hematology, Oncology and Cardiovascular Medicine, Kyushu University, Fukuoka, Japan.
Eishi BabaDepartment of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nobuaki OchiDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Toshio KuboDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Keita UchinoDepartment of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Yutaro KamiyamaDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Shinji NakaoDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
Shinobu TamuraDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Hitomi NishimotoDepartment of Nursing, Okayama University Hospital, Okayama, Japan.
Yasuhisa KatoDepartment of Drug Information, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Kanagawa, Japan.
Atsushi SatoDepartment of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Toshimi TakanoDepartment of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChemotherapy for breast cancer can cause neutropenia, increasing the risk of febrile neutropenia (FN) and serious infections. The use of granulocyte colony-stimulating factors (G-CSF) as primary prophylaxis has been explored to mitigate these risks. To evaluate the efficacy and safety of primary G-CSF prophylaxis in patients with invasive breast cancer undergoing chemotherapy.

methodsA systematic literature review was conducted according to the "Minds Handbook for Clinical Practice Guideline Development" using PubMed, Ichushi-Web, and the Cochrane Library databases. Randomized controlled trials (RCTs) and cohort studies assessing using G-CSF as primary prophylaxis in invasive breast cancer were included. The primary outcomes were overall survival (OS) and FN incidence. Meta-analyses were performed for outcomes with sufficient data.

resultsEight RCTs were included in the qualitative analysis, and five RCTs were meta-analyzed for FN incidence. The meta-analysis showed a significant reduction in FN incidence with primary G-CSF prophylaxis (risk difference [RD] = 0.22, 95% CI: 0.01-0.43, p = 0.04). Evidence for improvement in OS with G-CSF was inconclusive. Four RCTs suggested a tendency for increased pain with G-CSF, but statistical significance was not reported.

conclusionsPrimary prophylactic use of G-CSF is strongly recommended for breast cancer patients undergoing chemotherapy, as it has been shown to reduce the incidence of FN. While the impact on OS is unclear, the benefits of reducing FN are considered to outweigh the potential harm of increased pain.

Indexed as

Breast NeoplasmsFebrile NeutropeniaGranulocyte Colony-Stimulating FactorAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansPractice Guidelines as TopicRandomized Controlled Trials as TopicGranulocyte Colony-Stimulating FactorBreast cancerG-CSFMeta-analysisNeutropenia

Identifiers

PMID38900215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.